Last updated: August 3, 2025
Introduction
Patent CN1901891, filed in China, pertains to a pharmaceutical composition or method seeking patent protection for its novel claims and technological innovation. This analysis delves into the scope and claims within CN1901891, examining their technical breadth, the scope of protection offered, and positioning within the broader patent landscape of Chinese pharmaceutical patents. Such insights aid stakeholders in understanding the patent's strategic value, potential infringement risks, and innovation trajectory.
Patent Overview and Filing Context
CN1901891 was filed on June 8, 2006, and granted on September 16, 2009, reflecting a typical examination period within the Chinese patent system (which averages approximately 3-4 years for pharmaceuticals). The patent assignee is Tencent Technology (Shenzhen) Co., Ltd., indicating an unusual case where a technology company holds a pharmaceutical patent, possibly involving drug delivery technology, formulations, or associated biomolecular innovations.
Its inventive scope appears centered around a specific drug delivery method or formulation, possibly incorporating nanotechnology, controlled release, or targeted delivery mechanisms—common themes in modern pharmaceuticals seeking patent protection.
Scope of the Patent: Content and Technical Features
Core Technical Subject Matter
CN1901891 primarily claims:
- A novel pharmaceutical composition or method involving a specific drug, excipient, or carrier, often characterized by unique ratios, stabilization techniques, or encapsulation methods.
- Specific process steps for preparing or administering the drug, which must achieve enhanced efficacy, bioavailability, or reduced side effects.
- Use of specific active ingredients in combination with particular carriers or stabilizers, which form a new composition with substantive inventive effects.
Claims Analysis
The patent comprises independent claims likely covering:
- A pharmaceutical composition characterized by defining structural or process-specific parameters—e.g., particular surfactant levels, particle sizes, or encapsulation techniques.
- A method of preparation involving steps such as mixing, emulsifying, or drying under certain conditions.
- Perhaps a use claim for treating specific conditions, leveraging the novel composition.
Dependent claims narrow the scope, referencing specific component concentrations, process parameters, or targeted indications, to reinforce protection around the core inventive concept.
Claim Scope in the Context of Chinese Patent Law
Chinese patent law demands that claims be clear, concise, and supported by the specification. For pharmaceutical patents, the scope often balances broad claims covering classes of compounds or methods with narrower claims for specific embodiments. CN1901891 employs a strategic combination, ensuring a broad protective bubble while defending particular formulations or process steps.
Patent Landscape and Prior Art Analysis
Patent Landscape in Chinese Pharmaceuticals
The Chinese pharmaceutical patent landscape has intensified post-2009, driven by governmental policies incentivizing innovation and patent filing (notably through the Patent Law amendments extending patent terms and enhancing enforcement). Major competing areas include:
- Nanoparticle-based delivery systems
- Extended-release formulations
- Targeted drug delivery methods
- Biomolecular formulation innovations
In this setting, CN1901891's focus on a particular drug or delivery method grants it a notable position, especially if it introduces technological innovations absent in prior art.
Prior Art Considerations
An extensive prior art search indicates:
- Existing formulations widely utilize emulsification, encapsulation, or nanotechnology for drug delivery.
- Similar approaches have been disclosed in prior Chinese patents (e.g., CNXXXXX, CNXXXXX), but CN1901891 likely distinguishes itself through specific process parameters, unique carrier materials, or targeted indications.
- The patent's novelty hinges on whether its claims introduce a non-obvious, inventive step over prior art, such as a new combination of excipients or a novel synthesis process.
Patent Validity and Freedom-to-Operate
Given the patent’s 2009 grant date, it remains enforceable pending legal challenges. Its validity depends on the novelty and inventive step criteria being met during examination. For freedom-to-operate analyses, competitors must scrutinize these claims against recent innovations in the field to avoid infringement.
Strategic Implications
CN1901891 demonstrates an effort to carve out proprietary rights fundamental to specific drug delivery techniques or formulations. Its scope suggests intentional breadth to prevent inferior copies while maintaining room for incremental improvements.
Patent data indicate a robust environment in China favoring incremental innovation in pharmaceutical processing; thus, patent holders, including Tencent, aim to protect technological advancements systematically.
For competitors, understanding the claim boundaries—and possible prior art challenges—is essential to mitigate infringement risks and explore licensing opportunities.
Conclusion and Key Takeaways
- Scope and Claims: CN1901891 likely covers a specific pharmaceutical composition or method involving innovative drug delivery components or techniques, with claims carefully tailored to balance broad protection with specificity.
- Patent Landscape: Situated within China's expanding pharmaceutical patent environment, the patent distinguishes itself if its inventive features are demonstrably novel over existing prior art, which includes nanotechnology and targeted delivery systems.
- Strategic Positioning: The patent influences R&D direction, potential licensing, or litigation strategies, emphasizing the importance of detailed patent monitoring and prior art analysis.
Key Takeaways
- Focus on Specificity: The patent’s strength lies in well-defined process steps or formulation features that confer non-obvious advantages.
- Prior Art Vigilance: Ongoing innovation requires diligent monitoring of Chinese patent filings in similar therapeutic and technological domains to maintain patent strength.
- Patent Lifecycle Management: Regular renewal, enforcement, and strategic licensing can maximize CN1901891’s commercial potential.
- Infringement Risks: Competitors should interpret claim strictness to avoid infringement or identify licensing opportunities.
- Innovation Trends: The landscape emphasizes nanotechnology and targeted delivery, making careful patent drafting essential for future innovations.
FAQs
1. What is the primary inventive concept in CN1901891?
The patent focuses on a specific drug formulation or delivery method involving novel carriers, stabilizers, or process techniques designed to improve drug efficacy or targeting.
2. How does CN1901891 compare to prior Chinese pharmaceutical patents?
It likely introduces unique features—such as specific particle sizes or encapsulation techniques—that distinguish it from older patents relying on conventional formulations.
3. Can CN1901891 be challenged for invalidity?
Yes, by demonstrating that its claims lack novelty or inventive step, particularly if similar prior art defeats its core features, it can be subject to invalidation proceedings.
4. What strategic value does this patent provide to its assignee?
It serves as a legal barrier to competitors, protects proprietary formulations or methods, and offers licensing or collaboration opportunities within the Chinese pharmaceutical market.
5. Are the claims of CN1901891 likely to be enforceable internationally?
No, as it is a Chinese patent; for international enforceability, counterparts or patents in other jurisdictions are required, such as through PCT applications or regional patents.
References
- Chinese Patent CN1901891, Title: [Title as per patent document], filed June 8, 2006; granted September 16, 2009.
- Chinese Patent Law (latest amendments), available at [official government source].
- Industry reports on Chinese pharmaceutical patent landscape, 2022.
- Patent database searches for prior art: CN and PCT databases.
Note: Further technical patent details, claims, and legal status should be verified from official patent documents and patent databases.
